Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup - 26/07/22
Doi : 10.1016/S1470-2045(22)00139-5
Ignace Vergote, ProfMD a, b, ⁎ 
, Antonio Gonzalez-Martin, MD c, d, e, Domenica Lorusso, MD f, g, Charlie Gourley, MD h, i, Mansoor Raza Mirza, MD j, k, Jean-Emmanuel Kurtz, MD l, n, Aikou Okamoto, MD o, p, Kathleen Moore, MD q, r, Frédéric Kridelka, MD a, s, Iain McNeish, PhD t, u, Alexander Reuss, MSc v, x, Bénédicte Votan, MSc y, Andreas du Bois, MD v, z, Sven Mahner, MD v, aa, Isabelle Ray-Coquard l, m, Elise C Kohn, MD ab, Jonathan S Berek, MD ac, ad, David S P Tan, MD ae, af, ag, Nicoletta Colombo, MD ah, ai, aj, Rongyu Zang, MD ak, al, Nicole Concin, MD w, z, am, Dearbhaile O’Donnell, MD an, ao, Alejandro Rauh-Hain, MD ap, aq, C Simon Herrington, MD h, i, Christian Marth, MD w, am, Andres Poveda, MD c, ar, Keiichi Fujiwara, MD as, at, Gavin C E Stuart, MD au, av, Amit M Oza, MD aw, Michael A Bookman, MD q, ax
on behalf of the
, Antonio Gonzalez-Martin, MD c, d, e, Domenica Lorusso, MD f, g, Charlie Gourley, MD h, i, Mansoor Raza Mirza, MD j, k, Jean-Emmanuel Kurtz, MD l, n, Aikou Okamoto, MD o, p, Kathleen Moore, MD q, r, Frédéric Kridelka, MD a, s, Iain McNeish, PhD t, u, Alexander Reuss, MSc v, x, Bénédicte Votan, MSc y, Andreas du Bois, MD v, z, Sven Mahner, MD v, aa, Isabelle Ray-Coquard l, m, Elise C Kohn, MD ab, Jonathan S Berek, MD ac, ad, David S P Tan, MD ae, af, ag, Nicoletta Colombo, MD ah, ai, aj, Rongyu Zang, MD ak, al, Nicole Concin, MD w, z, am, Dearbhaile O’Donnell, MD an, ao, Alejandro Rauh-Hain, MD ap, aq, C Simon Herrington, MD h, i, Christian Marth, MD w, am, Andres Poveda, MD c, ar, Keiichi Fujiwara, MD as, at, Gavin C E Stuart, MD au, av, Amit M Oza, MD aw, Michael A Bookman, MD q, axon behalf of the
participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research*
Sven Mahner, Alexander Reuss, Andreas du Bois, Christoph Grimm, Christian Marth, Regina Berger, Nicole Concin, Ting-Chang Chang, Kazunori Ochiai, Val Gebski, Alison Davis, Philip Beale, Ignace Vergote, Frédéric Kridelka, Hannelore Denys, Vincent Vandecaveye, Francisco Jose Candido dos Reis, Maria Del Pilar Estevez Diz, Gavin Stuart, Helen MacKay, Mark Carey, David Cibula, Pavel Dundr (path), Oliver Dorigo, Jonathan Berek, Dearbhaile O'Donnell, Abu Saadeh, Ingrid Boere, Christianne Lok, Pluvio Coronado, Nelleke Ottevanger, David SP Tan, Joseph Ng, Antonio Gonzalez Martin, Ana Oaknin, Andres Poveda, Alejandro Perez Fidalgo, Alejandro Rauh-Hain, Karen Lu, Carlos López-Zavala, Eva María Gómez-García, Isabelle Ray-Coquard, Xavier Paoletti, Jean-Emmanuel Kurtz, Florence Joly, Bénédicte Votan, Michael Bookman, Kathleen Moore, Rebecca Arend, Keiichi Fujiwara, Hiroyuki Fujiwara, Kosei Hasegawa, Ilan Bruchim, Dalia Tsoref, Katsutoshi Oda, Aikou Okamoto, Takayuki Enomoto, Dayana Michel, Hee-Seung Kim, Jung-Yun Lee, Asima Mukhopadhyay, Dionyssios Katsaros, Nicoletta Colombo, Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Elise Kohn, Jung-Min Lee, Iain McNeish, Shibani Nicum, Laura Farrelly, Jalid Sehouli, Maren Keller, Elena Braicu, Line Bjørge, Mansoor Raza Mirza, Annika Auranen, Stephen Welch, Amit M Oza, Viola Heinzelmann, Charlie Gourley, Patricia Roxburgh, C Simon Herrington, Ros Glasspool, Rongyu Zang, Jianqing Zhu
a Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium
b University Hospitals Leuven, Leuven, Belgium
c Grupo Español de Cáncer de Ovario (GEICO), Madrid, Spain
d Clinica Universidad de Navarra, Madrid, Spain
e Program for Solid Tumors at Madrid, and Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain
f Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples, Italy
g Fondazione Policlinico Gemelli IRCCS, Rome, Italy
h Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research UK, Edinburgh, UK
i Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
j Nordic Society of Gynecologic Oncology Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark
k Rigshospitalet, Copenhagen, Denmark
l Groupe d’Investigateurs National des Etudes des Cancers Ovariens et du Sein (GINECO), Paris, France
m Centre Leon Berard and University Claude Bernard Lyon I, Lyon, France
n Strasbourg Cancer Institute, Strasbourg, France
o Japanese Gynecologic Oncology Group (JGOG), Tokyo, Japan
p The Jikei University School of Medicine, Tokyo, Japan
q Gynecologic Oncology Group-Foundation (GOG-F), Philadelphia, PA, USA
r OU Health Stephenson Cancer Center, Oklahoma City, OH, USA
s Centre Hospitalier Universitaire de Liège, Liège, Belgium
t National Cancer Research Institute (NCRI), London, UK
u Department of Surgery and Cancer, Imperial College London, London, UK
v Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Munich, Germany
w AGO -Austria, Innsbruck, Austria
x Coordinating Center for Clinical Trials, Philipps University, Marburg, Germany
y Association de Recherche Cancers Gynécologiques (ARCAGY)–GINECO, Paris, France
z Kliniken Essen Mitte (KEM), Essen, Germany
aa University Hospital, Ludwig Maximilians University, Munich, Germany
ab National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
ac Women’s Cancer Research Network-Cooperative Gynecologic Oncology Investigators (WCRN-COGI), Fresno, CA
ad Stanford Cancer Institute, Stanford, CA, USA
ae Asia Pacific Gynecologic Oncology Trials Group (APGOT), Seoul, South Korea
af Gynecologic Cancer Group Singapore (GCGS), Singapore
ag Cancer Science Institute, National University of Singapore, Singapore
ah Mario Negri Gynecologic Oncology (MaNGO), Milan, Italy
ai European Institute of Oncology, Milan, Italy
aj University of Milano-Bicocca, Milan, Italy
ak Shanghai Gynecologic Oncology Group (SGOG), Shanghai, China
al Zhongshan Hospital, Fudan University, Shanghai, China
am Medical University of Innsbruck, Innsbruck, Austria
an Cancer Trials Ireland (CTI), Dublin, Ireland
ao St James’s Hospital, Dublin, Ireland
ap Global Gynecologic Oncology Consortium (G-GOC), Houston, TX, USA
aq MD Anderson Cancer Center, The University of Texas, Houston, TX, USA
ar Hospital Quironsalud, Valencia, Spain
as Gynecologic Cancer Clinical Trials and Investigation Consortium (GOTIC), North Kanto, Japan
at Saitama Medical University International Medical Center, Saitama, Japan
au Canadian Cancer Trials Group (CCTG), Kingston, ON, Canada
av University of British Columbia, Vancouver, BC, Canada
aw Princess Margaret Hospital Consortium (PMHC), Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
ax San Francisco Medical Center, San Francisco, CA, USA
* Correspondence to: Prof Ignace Vergote, BGOG, University Hospitals Leuven, 3000 Leuven, Belgium BGOG University Hospitals Leuven Leuven 3000 Belgium
Summary |
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
Le texte complet de cet article est disponible en PDF.Plan
© 2022
Elsevier Ltd. Tous droits réservés.
Vol 23 - N° 8
P. e374-e384 - août 2022 Retour au numéro
Article précédent
- Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis
- Antonios Athanasiou, Areti Angeliki Veroniki, Orestis Efthimiou, Ilkka Kalliala, Huseyin Naci, Sarah Bowden, Maria Paraskevaidi, Marc Arbyn, Deirdre Lyons, Pierre Martin-Hirsch, Phillip Bennett, Evangelos Paraskevaidis, Georgia Salanti, Maria Kyrgiou
- Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP
- Maria Kyrgiou, Antonios Athanasiou, Marc Arbyn, Sigurd F Lax, Maria Rosaria Raspollini, Pekka Nieminen, Xavier Carcopino, Jacob Bornstein, Murat Gultekin, Evangelos Paraskevaidis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?